Sartorius stock trades at EUR 256.05 with P/ E 89.8

Published on 10/12/2026 at 13:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Barclays lifted its target to EUR 310.00 on September 30, 2026. Sartorius stock costs EUR 256.05 on October 12, 2026, 1.21 percent above EUR 253.00.

Key points in brief

Sartorius stock was trading at EUR 256.05 at Lang & Schwarz on October 12, 2026, up 1.21 percent versus the October 9 Xetra close.
The stock's P/E ratio was 89.8, compared with 35.4 for Thermo Fisher and 39.1 for Danaher.
Barclays raised its Sartorius target from EUR 300.00 to EUR 310.00 on September 30, 2026.
Sartorius is scheduled to present its nine-month 2026 results on October 22, 2026.

Fotorealistische Bioreaktor-Anlage in Reinraumhalle mit Edelstahltanks und Technikern — Sartorius AG (Vz.) DE0006292006 zeigt fotorealistisch eine sterile Bioreaktor-Anlage mit Technikern in weißer Reinraum-Schutzkleidung, Illustration mit AI erstellt.

Sartorius stock (ISIN DE0007165631) was trading at EUR 256.05 at Lang & Schwarz on October 12, 2026 at 1:51 p.m. CEST, up 1.21 percent versus the October 9 Xetra close. The valuation marker remains a P/E ratio of 89.8, making the price level more important than the modest intraday move.

Price stays near the yearly high

The current quote is EUR 15.85 below the 52-week high of EUR 271.90 and EUR 57.55 above the 52-week low of EUR 198.50. That places Sartorius 5.83 percent below its yearly high and 28.99 percent above its yearly low, using the same October 12, 2026 quote snapshot.

Lang & Schwarz showed a bid of EUR 255.90 and an ask of EUR 256.20 at 1:51 p.m. CEST. The finance quote for Sartorius preference shares showed 5,262 shares traded against an average volume of 97,863, with the volume figures dated October 12, 2026.

Valuation exceeds large peers

Sartorius carries a P/E ratio of 89.8 and a market capitalization of EUR 17.6 billion as of October 12, 2026. Thermo Fisher Scientific traded at USD 658.02 on October 9, 2026, with a P/E ratio of 35.4 and a market capitalization of USD 243.3 billion, while Danaher stood at USD 219.87 with a P/E ratio of 39.1 and a market capitalization of USD 154.6 billion on the same date.

FinanzNachrichten reported on September 30, 2026 that Barclays raised its Sartorius target from EUR 300.00 to EUR 310.00 and retained an Overweight rating. The new target lies 21.07 percent above the Lang & Schwarz price, a gap that reflects the difference between the analyst's valuation framework and the current market quote.

Comparison with peers

Sartorius: plus 1.21 percent, P/E 89.8, market capitalization EUR 17.6 billion

Thermo Fisher Scientific (NYSE, USD): plus 0.93 percent, P/E 35.4, market capitalization USD 243.3 billion

Danaher (NYSE, USD): plus 1.11 percent, P/E 39.1, market capitalization USD 154.6 billion

Results date is October 22

Sartorius lists its nine-month 2026 results and conference call for October 22, 2026 at 1:00 p.m. CEST. The date is the next scheduled reporting checkpoint for a stock whose P/E ratio stands well above the two US peers listed above.

The stock was trading at EUR 256.05 at Lang & Schwarz on October 12, 2026 at 1:51 p.m. CEST, up 1.21 percent versus the Xetra close of October 9, 2026 at EUR 253.00. The further course of trading is shown by the continuously updated real-time quote of Sartorius stock.